Skip to Main Content

Good morning, everyone, how are you today? We are doing just fine, thank you, as sunny skies and cool breezes envelop the unusually quite Pharmalot campus. Our short person is hunched over a laptop once again for another day of learning and our official mascot is snoozing away in a corner. All of which means we are free to focus on the tasks at hand — brewing cups of stimulation and foraging for items of interest. On that note, here is the latest batch of tidbits. We hope your day goes well and you conquer the world. And of course, do stay in touch …

In a significant move to combat the Covid-19 pandemic, the U.S. government agreed to support a controversial proposal to temporarily waive intellectual property rights for vaccines in a bid to increase global supplies of desperately needed doses, STAT reports. Ultimately, a waiver would make it easier for countries that permit compulsory licensing to allow a manufacturer to export vaccines. The move came amid growing concern that low- and middle-income countries were being left out after wealthy nations reached deals with vaccine makers.


The stunning U.S. endorsement of a proposal to waive Covid-19 vaccine intellectual property has won plaudits for President Biden and roiled the global pharmaceutical industry. But, at least in the short term, this is likely to be more of a symbolic milestone than a turning point in the pandemic, STAT explains. “My take is: By itself, it will not get us much benefit in increased manufacturing capacity,” said Prashant Yadav, a supply chain expert and senior fellow at the Center for Global Development. “But as part of a larger package, it can.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!